WON TECH Co.,Ltd.

KOSDAQ:A336570 Stock Report

Market Cap: ₩393.5b

WON TECHLtd Valuation

Is A336570 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A336570 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A336570 (₩4405) is trading below our estimate of fair value (₩15083.9)

Significantly Below Fair Value: A336570 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A336570?

Key metric: As A336570 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A336570. This is calculated by dividing A336570's market cap by their current earnings.
What is A336570's PE Ratio?
PE Ratio13.9x
Earnings₩28.36b
Market Cap₩393.53b

Price to Earnings Ratio vs Peers

How does A336570's PE Ratio compare to its peers?

The above table shows the PE ratio for A336570 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average7.7x
A145720 Dentium
5.3x13.8%₩501.0b
A206640 Boditech Med
11.7x16.6%₩357.3b
A043150 Value Added Technology
5.7x10.8%₩300.8b
A041830 InBodyLtd
7.9x15.5%₩289.2b
A336570 WON TECHLtd
13.9x38.4%₩393.5b

Price-To-Earnings vs Peers: A336570 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the peer average (50x).

Price to Earnings Ratio vs Industry

How does A336570's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A035610 Solborn
2.5xn/aUS$67.17m
No more companies available in this PE range
A336570 13.9xIndustry Avg. 12.9xNo. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A336570 is expensive based on its Price-To-Earnings Ratio (13.9x) compared to the KR Medical Equipment industry average (12.9x).

Price to Earnings Ratio vs Fair Ratio

What is A336570's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A336570 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.9x
Fair PE Ratio25.5x

Price-To-Earnings vs Fair Ratio: A336570 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the estimated Fair Price-To-Earnings Ratio (25.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A336570 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩4,405.00
₩10,633.33
+141.4%
32.5%₩15,000.00₩4,700.00n/a9
Nov ’25₩5,660.00
₩11,755.56
+107.7%
18.0%₩15,000.00₩9,000.00n/a9
Oct ’25₩7,000.00
₩11,555.56
+65.1%
20.4%₩15,000.00₩8,000.00n/a9
Sep ’25₩5,870.00
₩11,555.56
+96.9%
20.4%₩15,000.00₩8,000.00n/a9
Aug ’25₩6,830.00
₩12,166.67
+78.1%
13.7%₩15,000.00₩10,000.00n/a9
Jul ’25₩8,080.00
₩12,388.89
+53.3%
12.0%₩15,000.00₩10,500.00n/a9
Jun ’25₩7,860.00
₩12,666.67
+61.2%
10.5%₩15,000.00₩11,000.00n/a9
May ’25₩10,340.00
₩13,500.00
+30.6%
8.3%₩15,000.00₩12,000.00n/a6
Apr ’25₩10,410.00
₩13,500.00
+29.7%
8.3%₩15,000.00₩12,000.00n/a6
Mar ’25₩8,450.00
₩13,500.00
+59.8%
8.3%₩15,000.00₩12,000.00n/a6
Feb ’25₩7,870.00
₩14,666.67
+86.4%
10.9%₩17,000.00₩12,000.00n/a6
Jan ’25₩9,330.00
₩15,083.33
+61.7%
8.6%₩17,000.00₩13,000.00n/a6
Dec ’24₩10,510.00
₩15,083.33
+43.5%
8.6%₩17,000.00₩13,000.00n/a6
Nov ’24₩9,230.00
₩16,250.00
+76.1%
15.0%₩21,000.00₩13,000.00₩5,660.006
Oct ’24₩11,500.00
₩17,375.00
+51.1%
15.9%₩22,000.00₩15,000.00₩7,000.004
Sep ’24₩14,270.00
₩17,375.00
+21.8%
15.9%₩22,000.00₩15,000.00₩5,870.004
Aug ’24₩10,970.00
₩13,000.00
+18.5%
33.1%₩19,000.00₩8,000.00₩6,830.004
Jul ’24₩10,400.00
₩9,666.67
-7.1%
12.9%₩11,000.00₩8,000.00₩8,080.003
Jun ’24₩8,630.00
₩9,000.00
+4.3%
11.1%₩10,000.00₩8,000.00₩7,860.002
May ’24₩6,320.00
₩7,500.00
+18.7%
6.7%₩8,000.00₩7,000.00₩10,340.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Access Bio

₩191.4b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,660.00

7D

-3.4%

1Y

-38.1%

Wonbiogen

₩44.6b

Develops and sells medical equipment in South Korea.

A307280

₩1,258.00

7D

-3.7%

1Y

-20.0%

Boditech Med

₩357.3b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩16,260.00

7D

-1.5%

1Y

-5.3%